



EAST LANCASHIRE HEALTH ECONOMY MEDICINES MANAGEMENT BOARD

MINUTES OF THE MEETING HELD ON WEDNESDAY 19TH OCTOBER 2016
AT 12.30pm

IN SEMINAR ROOM 6, LEARNING & DEVELOPMENT CENTRE,
ROYAL BLACKBURN HOSPITAL

PRESENT:

Dr D Gavan (DG)	Consultant Radiologist ELHT (chairperson)
Dr L Rogan (LR)	Head of Medicines Commissioning NHS EL CCG
Mrs C Woffindin (CW)	Medicines Information Manager, ELHT
Mr V Goodey (VG)	Assistant Director of Pharmacy, Clin Service ELHT
Dr S Jackson (SJ)	Clinical Commissioning Group MM Lead, GP EL
Mrs C Dugdale (CD)	Meds Management Pharmacist NHS BwD CCG
Dr T McKenzie (TM)	GP, EL CCG
Mr J Vaughan (JV)	Commissioning Support Pharmacist NHS EL/BwD

In Attendance

Ms L Prince	Medicines Management Technician EL CCG
-------------	----------------------------------------

2016/133: APOLOGIES:

Mr N Fletcher (NF)	Director of Pharmacy ELHT
Mr A Gray (AG)	Clinical Pharmacist, ELHT
Dr K Burch (KB)	Consultant Microbiologist ELHT
Ms A Atkinson (AA)	Pharmacist LCFT (representing Mrs C Harding)
Dr J Randall (JR)	GP, NHS BwD CCG
Mrs D Hogg (DH)	Non-Medical Prescribing Lead, ELHT

2016/134: DECLARATION OF INTEREST

None declared – relevant to agenda items.

2016/135: MINUTES OF SEPTEMBER MEETING:

Accepted as a correct record.

2016/136: MATTERS ARISING:

2015/101: NOAC's and Elective Surgery – draft guidance is being developed following new BSH perioperative guidelines. Once finalised it needs to be cross-checked against the new Anticoagulant prescribing guidance document.

2015/132: Formulary Updates: Oxycodone – draft leaflet to be circulated with comment back to VG by 28th Oct.

2016/049: Antibiotic Supplies for Paediatrics – Information is on the copy of the OP prescription or discharge letter. No further action required.

2016/087: Formulary Updates – review of Parkinson’s preparations and brands – ongoing, VG to follow up.

2016/105: NICE Recommendations (from June) – Alirocumab and Evolocumab – these are both CCG commissioned and will remain RED traffic light.

2016/120: ELHT Alcohol Pathway – awaiting information from Alcohol group. LR shared Manchester’s shared care document as a possible example to use. LR to share with Inspire and ask for comments for next meeting.

2016/125: ELHE Managed Introduction of New Medicines – amendments completed and can now be taken to trust’s boards.

2016/128: NICE Recommendations (from August) – Degarelix – The rebate is available to CCG’s. Traffic light can be changed to AMBER. **Traffic Light: AMBER**

2016/124: ELHE Identification Guide for Formulary Preferred Inhalers – agreed at last meeting but needs information on Step 3 amending to be in line with latest guidance and new inhalers adding

2016/137: LMMG CONSULTATIONS (for Nov LMMG)

Oral Anticoagulants in AF Prescribing Guide – comments: -

Page 2: 4.1 - one GP queried the use of CHA2DSVASc for patients with atrial flutter or continuing risk of arrhythmia recurrence after cardioversion.

It is included in NICE CG180.

Page 5: 4.2 – poor choice of words ‘main stone’, suggest ‘standard’ or similar

Page 6: 4.2.2 – some of the wording in the table is not considered specific enough, eg more frequent, monitoring may be required

Page 6: 4.2.3 – creatinine clearance, should be based on IBW not actual body weight.

Page 7: European guidelines box – the UKMi link does not work

Page 7: 4.3.2 – states no specific monitoring but the NOAC cards that we give out contain specific monitoring – the two need to match, could the card details be added to this document.

Page 7: 4.3.2 –second paragraph, suggest need to include information on how far Hb should fall before stopping the NOAC. Is it appropriate to prescribe iron?

Page 13 & 14: - the need for these pages was questioned as the information is already on page 2 & 3 (for page 13) and 4 & 2 (for page 14.)

Page 15: above the table there is a reference to ‘see the LMMG NOAC Prescribing Guide’ but this all one document now.

Page 18: Counselling checklist box – wording of 9 is not clear and there are many more counselling points for warfarin.

An additional point for stopping anti-platelets should be included.

In general – could it be made more reader friendly?

Melatonin Recommendation and Position Statement – this is to recommend use of the licensed product (Circadin) off label where appropriate. A suggestion from a paediatric CAMHS consultant is that ‘neurological conditions’ is changed to ‘neurodevelopmental disorders’ and for adult use it should also include all children previously receiving melatonin for neurological development not just those from CAMHS. The use of melatonin was questioned by the CCG based on the poor evidence and suggested a preference for a black traffic light. Secondary care would want to see Amber traffic light for the unlicensed preparation.

Guidelines for Good Prescribing in Primary Care – no comments

Resolved: CW to send responses to LMMG.

2016/138: LMMG RECOMMENDATIONS (from September)

Colesevaem recommendation - for use in familial hypercholesterolaemia. LMMG recommendation accepted as written for ELHE. **Traffic light: BLACK**

Tapentadol recommendations – for treatment of neuropathic pain in non-palliative care patients and for non-specific pain. LMMG recommendations accepted as written for ELHE. **Traffic light: BLACK**

Use in palliative care still under review.

Psoriasis Biologics Pathway – the commissioning pathway for biologics in psoriasis has been updated with biosimilars included and flexs outside of NICE. Accepted as written for ELHE.

E-cigarettes Position Statement – accepted as written for ELHE. **Traffic light: BLACK**

LMWH Summary Prescribing Guide – accepted for information only. ELHE to continue to use the ELHE LMWH Best Practice Guide.

Ulipristal Prescribing Information Guide – concerns expressed that this doesn't contain specific contraceptive counselling information and recommendation to specify course length for individual patient. Comments to be fed back to LMMG.

Resolved: Recommendations accepted for ELHE as above. Comments on Ulipristal to LMMG.

2016/139: FORMULARY UPDATES

Sodium Benzoate – as this is NHS England commissioned, it should be Red traffic light. To remain amber for current patients until alternative arrangements are made, but red for new patients.

Metolazone – request to change traffic light from Red to amber but as this is an unlicensed preparation it will remain Red. Ongoing supply arrangements should be made in secondary care.

Perampanel – not discussed

NOACs – agreed to change traffic light from Amber to Green to reflect the use of the NOACs.

Traffic light: GREEN

Resolved: Formulary to be updated as above.

2016/140: ISCOMAT PROGRAMME

For information – the CCG will be participating in this transition of care study. ELHT also participating.

Resolved: ELMMB acknowledged.

2016/141: H-PYLORI ERADICATION GUIDELINES

The H-Pylori guidelines in the formulary to be updated in line with NICE. JV/LR to update on website.

Resolved: ELMMB approved updated H-Pylori guidelines.

2016/142: LCFT QUETIAPINE MR TO QUETIAPINE SWITCHING GUIDELINES

Document supports the LCFT recommendation to switch patients from Quetiapine MR to plain quetiapine.

Resolved: ELMMB approved Quetiapine switching guidelines.

2016/143: PRIMARY CARE ANTIMICROBIAL GUIDELINES

First line UTI and first line acne treatments have been updated as part of guideline review. Meningitis section to have ceftriaxone included in addition to benzylpenicillin. JV/LR to update on website.

Resolved: Updated sections of Primary Care Antimicrobial guidelines approved.

2016/144: MEDICATION ERROR CHECKLIST AND SAFEGUARDING

For information – these documents will be added to care home section of website.

Resolved: ELMMB acknowledged.

2016/145: OXYCODONE IN CANCER PAIN - NICE

This evidence from NICE suggests oxycodone is no more effective than morphine. To ask Palliative Care consultant for views.

Resolved: Obtain Palliative care consultants views on document.

2016/127: NICE RECOMMENDATIONS (from July)

Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (TAG406) is recommended as an option by NICE. Approved in line with NICE. NHS England commissioned. **Traffic Light: RED**

Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors (TAG 407) is recommended as an option by NICE. Approved in line with NICE. CCG commissioned. **Traffic Light: RED**

Pegaspargase for treating acute lymphoblastic leukaemia (TAG 408) is recommended as an option by NICE. Approved in line with NICE. NHS England commissioned. **Traffic Light: RED**

Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion (TAG 409) is recommended as an option by NICE. Approved in line with NICE. CCG commissioned. **Traffic Light: RED**

Talimogene laherparepvec for treating unresectable metastatic melanoma (TAG 410) is recommended as an option by NICE. Approved in line with NICE. NHS England commissioned. **Traffic Light: RED**

Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer (TAG 411) is not recommended as an option by NICE. **Traffic Light: BLACK**

Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TAG 412) is recommended as an option by NICE. Approved in line with NICE. NHS England commissioned. **Traffic Light: RED**

STANDING ITEMS

2016/147: FOR ACTION/INFORMATION: LANCASHIRE MEDICINES MANAGEMENT GROUP MINUTES – September 2016

Minutes acknowledged

2016/148: FOR ACTION/INFORMATION: LANCASHIRE CARE FOUNDATION TRUST D&T MINUTES – September 2016

Minutes acknowledged

DATE OF NEXT MEETING – Next meeting is **Wednesday 16th November 2016 12.30pm**, Seminar Room 9, Learning and Development Centre, RBH.

**ACTION SHEET FROM
EAST LANCASHIRE HEALTH ECONOMY
MEDICINES MANAGEMENT BOARD**

WEDNESDAY 19th OCTOBER 2016

MINUTE NUMBER	DESCRIPTION	ACTION	DATE
2015/101	NOAC's And Elective Surgery – guideline in progress	VG	June 16
2015/132	Formulary Updates – Oxycodone – patient leaflet for brands/generics of opioids to be sent out for comment	VG	Nov 16
2016/087	Formulary Updates – review Parkinson's preparations and brands	VG	Jul 16
2016/120	ELHT Alcohol Pathway – check place in therapy of disulfiram. Obtain comments from Inspire.	CW LR	Oct 16
2016/124	ELHE Identification Guide for Formulary Preferred Inhalers – information on step 3 to be amended in line with latest guidance	LR/JV	Nov 16
2016/138	LMMG Recommendations from September – send Ulipristal comments to LMMG	CW	Nov 16
2016/145	Oxycodone In Cancer Pain – NICE – obtain view of palliative care consultant.	VG/CW	Nov 16